The responses, guidance, and advisories provided by the Pharmaceutical Advertising Advisory Board (PAAB),
including but not limited to those available through the PAAB Forum, the PAAB website, and any PAAB
correspondences, are specifically intended to assist individuals navigating the PAAB preclearance system.
Repurposing or reproducing this content without written consent from the PAAB Commissioner is strictly
prohibited. This prohibition includes, but is not limited to, use in machine learning or AI models.
752: My question is specifically regarding a sales rep emailing a (known, consented) HCP one on one with: A) A one line message that a product has now received Health Canada approval with approved indication. No claims, data etc B) A request to HCP to discuss Patient Support Program which may include info on the PAAB approved patient enrolment form Is this communication different if a Medical Affairs staff member sends the email? thanks very much.
FYI post-approval change/preclearance exemption/what requires review/PAAB scope
1
Posts
1
Posters
947
Views
1
Watching
-
A) Yes this message requires review.
B) Yes this would also require review. It remains an unsolicited message to promote a product or offering from the company and therefore would not be perceived as different if it came from medical affairs. We would also recommend reviewing industry codes such as the Innovative Medicines Canada Code of Ethical Practices which state that medical/regulatory/scientific personnel may not sign promotional materials. See question above.
